Skip to main content

Table 4 Example of tabular reporting of patient characteristics [180].

From: Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration

   Patients   
  All CK-19mRNA + CK-19mRNA -  
Characteristic Number % Number % Number % P
Patients enrolled 444   100 181   40.8 263   59.2  
Age, years           
   Median   54    54    55   
   Range   26 to 78    26 to 74    30 to 78   0.752
Menopausal status           0.075
   Premenopausal 191   43 87   45.5 104   54.5  
   Postmenopausal 253   57 94   37.2 159   62.8  
Tumor size           0.648
   T1 157   35.4 61   38.9 96   61.1  
   T2 251   56.5 103   41 148   59  
   T3 36   8.1 17   47.2 19   52.8  
Histology grade           0.316
   I/II 204   46 87   42.6 117   57.4  
   III 191   43 72   37.7 119   62.3  
   Unknown 49   11 22    27    
Infiltrated axillary lymph nodes           0.538
   0 163   36.7 61   37.4 102   62.6  
   1 to 3 122   27.5 53   43.5 69   56.5  
   ≥4 159   35.8 67   42.1 92   57.9  
ER           0.779
   Negative 175   39.4 71   40.6 104   59.4  
   Positive 260   58.6 109   41.9 151   58.1  
   Unknown 9   2 1    8    
PR           0.126
   Negative 234   52.7 89   38 145   62  
   Positive 201   45.3 91   45.3 110   54.7  
   Unknown 9   2 1    8    
HER2           0.897
   0, 1+ 290   65.3 122   42.1 168   57.9  
   2+ 53   11.9 21   39.6 32   60.4  
   3+ by IHC 88   19.8 35   39.8 53   60.2  
   Unknown 13   3 3    10    
Adjuvant chemotherapy           0.425
   CMF 43   9.7 14   32.6 29   67.4  
   FEC 209   47.1 84   40.2 125   59.8  
   EC-T 192   43.2 83   43.2 109   56.8  
Surgery           0.478
   L 310   69.8 123   39.7 187   60.3  
   M 134   30.2 58   43.3 76   56.7  
Radiotherapy           0.799
   No 81   18.2 32   39.5 49   60.5  
   Yes 363   81.8 149   41 214   59  
  1. CK-19: cytokeratin-19; CMF: cyclophosphamide, methotrexate, fluorouracil; EC-T: epirubicin, cyclophosphamide, docetaxel; ER: estrogen receptor; FEC: fluorouracil, epirubicin, cyclophosphamide; IHC: immunohistochemistry; L: lumpectomy; M: mastectomy; PR: progesterone receptor.